Market overview
The global HIV self-testing market is worth USD 259 mn in 2026 and is forecast to reach USD 534 mn by 2036, growing at a 7.5% CAGR. United States is the largest country market and Oral fluid is the largest by sample segment.
| Scope | Home HIV tests that people use on themselves: oral fluid and finger-prick blood kits sold through public programmes, pharmacies and online. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 240 mn |
| Value 2026 | USD 259 mn |
| Value 2036 | USD 534 mn |
| CAGR 2026-2036 | 7.5% |
| Volume 2026 | 19.6 million kits |
| Volume 2036 | 44.8 million kits |
| Average price 2026 | USD 13.2 per kit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
HIV Self-testing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 259 mn |
| 2027 | USD 279 mn |
| 2028 | USD 300 mn |
| 2029 | USD 322 mn |
| 2030 | USD 346 mn |
| 2031 | USD 372 mn |
| 2032 | USD 400 mn |
| 2033 | USD 430 mn |
| 2034 | USD 462 mn |
| 2035 | USD 497 mn |
| 2036 | USD 534 mn |
HIV Self-testing market segmentation
By sample
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral fluid | 52.0% | 44.4% | USD 135 mn | 5.8% |
| Finger-prick blood | 40.0% | 47.3% | USD 104 mn | 9.3% |
| Dual and other formats | 8.0% | 8.2% | USD 21 mn | 7.8% |
By channel
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Public programmes and donors | 52.0% | 52.9% | USD 135 mn | 7.7% |
| Online | 24.0% | 26.8% | USD 62 mn | 8.7% |
| Retail and pharmacy | 24.0% | 20.3% | USD 62 mn | 5.7% |
By test generation
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Third-generation antibody | 62.0% | 54.0% | USD 161 mn | 6.0% |
| Fourth-generation antigen and antibody | 24.0% | 30.0% | USD 62 mn | 9.9% |
| Multiplex and combined tests | 14.0% | 16.0% | USD 36 mn | 8.9% |
By target population
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| General adults | 40.0% | 36.0% | USD 104 mn | 6.4% |
| Key populations | 34.0% | 36.0% | USD 88 mn | 8.1% |
| Adolescents and young people | 14.0% | 16.0% | USD 36 mn | 8.9% |
| Partners of diagnosed clients | 12.0% | 12.0% | USD 31 mn | 7.5% |
By testing setting
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Unsupervised home | 60.0% | 56.0% | USD 156 mn | 6.8% |
| Community and outreach assisted | 28.0% | 30.0% | USD 73 mn | 8.2% |
| Clinic and pharmacy supervised | 12.0% | 14.0% | USD 31 mn | 9.2% |
Top 25 countries for HIV self-testing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 68.0% of 2026 revenue and the 25 countries below together hold 91.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 44 mn | 17.0% | USD 89 mn | 7.2% |
| 2 | South Africa | USD 36 mn | 14.0% | USD 80 mn | 8.2% |
| 3 | Nigeria | USD 18 mn | 7.0% | USD 36 mn | 7.2% |
| 4 | Kenya | USD 16 mn | 6.0% | USD 32 mn | 7.3% |
| 5 | Zimbabwe | USD 13 mn | 5.0% | USD 26 mn | 7.3% |
| 6 | Mozambique | USD 13 mn | 5.0% | USD 26 mn | 7.3% |
| 7 | Brazil | USD 10 mn | 4.0% | USD 23 mn | 8.3% |
| 8 | United Kingdom | USD 10 mn | 4.0% | USD 20 mn | 6.7% |
| 9 | Zambia | USD 7.8 mn | 3.0% | USD 15 mn | 7.1% |
| 10 | India | USD 7.8 mn | 3.0% | USD 21 mn | 10.4% |
| 11 | Uganda | USD 7.0 mn | 2.7% | USD 13 mn | 6.1% |
| 12 | Tanzania | USD 7.0 mn | 2.7% | USD 16 mn | 8.5% |
| 13 | Ethiopia | USD 6.1 mn | 2.4% | USD 14 mn | 8.5% |
| 14 | Ghana | USD 4.4 mn | 1.7% | USD 9.9 mn | 8.5% |
| 15 | Democratic Republic of the Congo | USD 4.4 mn | 1.7% | USD 12 mn | 10.5% |
| 16 | France | USD 4.4 mn | 1.7% | USD 6.7 mn | 4.4% |
| 17 | Cameroon | USD 3.5 mn | 1.4% | USD 6.4 mn | 6.2% |
| 18 | Angola | USD 3.5 mn | 1.4% | USD 7.9 mn | 8.5% |
| 19 | Ivory Coast | USD 3.5 mn | 1.4% | USD 6.4 mn | 6.2% |
| 20 | Canada | USD 3.5 mn | 1.4% | USD 5.4 mn | 4.4% |
| 21 | Philippines | USD 3.5 mn | 1.4% | USD 7.9 mn | 8.5% |
| 22 | Botswana | USD 2.6 mn | 1.0% | USD 4.8 mn | 6.2% |
| 23 | Namibia | USD 2.6 mn | 1.0% | USD 4.8 mn | 6.2% |
| 24 | Rwanda | USD 2.6 mn | 1.0% | USD 5.9 mn | 8.5% |
| 25 | Thailand | USD 2.6 mn | 1.0% | USD 4.8 mn | 6.2% |
| Rest of world | USD 22 mn | 8.3% | USD 41 mn | 6.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- OraSure Technologies
- Abbott
- Viatris
- SD Biosensor
Group 2: Regional and specialist players
- Atomo Diagnostics
- bioLytical Laboratories
- Biosynex
- Trinity Biotech
- Premier Medical Corporation
- ABON Biopharm
- CTK Biotech
- AAZ
Group 3: Emerging and niche players
- Wondfo
- Hangzhou Alltest Biotech
- Innovita Biological Technology
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the HIV self-testing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.5% is calculated from the resulting values.
The market is divided by sample, by channel, by test generation, by target population, by testing setting. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the HIV self-testing market?
The global HIV self-testing market is estimated at USD 240 mn in 2025 and USD 259 mn in 2026.
How fast will the HIV self-testing market grow?
It is forecast to reach USD 534 mn by 2036, a compound annual growth rate of 7.5% from 2026, an increase of USD 275 mn.
Which country is the largest market for HIV self-testing?
United States is the largest market by revenue at USD 44 mn in 2026, 17.0% of the global total. The three largest countries together hold 38.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 10.4% a year from 2026 to 2036.
Which HIV self-testing segment is largest?
In the by sample split, Oral fluid is the largest segment with 52.0% of 2026 revenue.
Who are the leading HIV self-testing companies?
Global leaders include OraSure Technologies, Abbott, Viatris, SD Biosensor.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Synthetic Clinical Trial DataUSD 260 mn · 22.0% CAGR
- Dental Oral MicrobiomeUSD 255 mn · 10.0% CAGR
- Automated CPR DeviceUSD 253 mn · 5.5% CAGR
- Augmented Glenoid SystemsUSD 251 mn · 8.5% CAGR
- Dengue VaccinesUSD 247 mn · 22.0% CAGR
- Ascites Fluid Removal DevicesUSD 276 mn · 6.0% CAGR
- Medical Device Cyber Risk QuantificationUSD 244 mn · 15.0% CAGR
- Continuous Peripheral Nerve Block CatheterUSD 243 mn · 5.0% CAGR
← Good Manufacturing Practice Compliance Handheld Point-of-Care Ultrasound →